The PPAR subfamily of nuclear hormone receptors also includes PPARα (target of fibrate class lipid lowering drugs) and PPARγ (target of the rosiglitazone-family of anti-diabetes drugs), all of which form heterodimers with the RXRα subunit of retinoid receptors and require binding of ligands in order to bind cognate promoters and transactivate distinct set of target genes. ❋ Malgorzata Romanowska Et Al. (2010)
This cell-based assay technology identifies molecules acting through pairs of different GPCRs, known as GPCR heterodimers. ❋ Unknown (2010)
Microtubules are dynamic structures composed of α-β-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs. ❋ Maria Kavallaris (2010)
It could also be seen that the size of the complex formed with U937 nuclear extract was lower as compared to that formed with nuclear extract from 293T cells over - expressing c-Rel probably pointing to the formation of P65 c-Rel homodimers in the case of 293T cells over-expressing c-Rel as compared to the formation of P50/P65-c-Rel heterodimers in U937 cells. ❋ Anil K. Singh Et Al. (2010)
In particular, in silico docking analysis showed that GD3 has a high affinity for the pore formed by four tubulin heterodimers (type I pore), thus suggesting a possible interaction between tubulin and GD3. ❋ Maurizio Sorice Et Al. (2010)
Three major inhibitory NK receptors are found on peripheral as well as on decidual NK cells: the CD94/NKG2 heterodimers which recognize the HLA-E molecule loaded with MHC class I signal peptide ❋ Tsufit Gonen-Gross Et Al. (2010)
Fra-1 forms activator protein-1 heterodimers with Jun partners and drives gene transcription. ❋ Qingshan Wang (2010)
NKG2A is an inhibitory NK receptor that has been reported to form disulfide-linked heterodimers with invariant CD94. ❋ Vivien Béziat Et Al. (2010)
The histone fold is a structural element that facilitates heterodimerization, and histone fold heterodimers play crucial roles in gene regulation. ❋ Unknown (2009)
Extend the Lipton Study in metastatic breast cancer by making additional VeraTag measurements, such as those for p95, HER3 and HER heterodimers, in existing patient samples to investigate the relationship between those biomarkers and clinical outcomes, and subsequently submitting study results for presentation and publication. ❋ Unknown (2009)
Using glutathione S-transferase pulldown experiments, we provide evidence that heterodimers are required for efficient binding of importin 13 because the monomers alone do not significantly interact. ❋ Unknown (2009)
Our results from in vitro nuclear import assays with permeabilized cells and in vivo cotransfection experiments reveal that importin 13 facilitates nuclear import of both histone fold heterodimers. ❋ Unknown (2009)
Binding of activators to LXR/RXR heterodimers results in a conformational change and ABCA1 transcription ❋ Li Zhou Et Al. (2009)
These proteins interact with each other and assemble as non-covalent heterodimers and their TMs play a major role in heterodimer formation, membrane anchoring and endoplasmic reticulum retention ❋ Unknown (2009)
Interestingly, both β-arrestin 1 and β-arrestin 2 are required to promote the activation of Akt. The requirement of both proteins might be indicative of a need to form heterodimers to activate the β-arrestin-dependent signaling pathway as it was described for MAPK activation ❋ Unknown (2009)
PGHSs are homodimers that display half of sites COX activity with AA; thus, PGHSs function as conformational heterodimers. ❋ Unknown (2009)
Conduct additional studies in both metastatic and adjuvant breast cancer using an expanded menu of VeraTag assays (which may include: HER2 total protein and homodimer, HER1 total protein and homodimer, HER3 total protein, HER1: 2 and HER2: 3 heterodimers, HER3-PI3K, and p95) to investigate why patients fail targeted therapies, and thus to understand how targeted inhibitors of the EGFR-family of receptors might be combined for better patient outcomes. ❋ Unknown (2009)
Extend the FINHER adjuvant study by making additional VeraTag measurements, such as those for p95, HER3 and HER heterodimers, in existing patient samples to investigate the relationship between those biomarkers and clinical outcomes, and subsequently submitting study results for presentation and publication. ❋ Unknown (2009)
